MediWound (NASDAQ:MDWD) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

MediWound Ltd. (NASDAQ:MDWD) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $16.82 and traded as low as $14.70. MediWound shares last traded at $14.82, with a volume of 64,553 shares trading hands.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Oppenheimer restated an “outperform” rating and issued a $32.00 price target (down from $33.00) on shares of MediWound in a research note on Wednesday, May 27th. Wall Street Zen upgraded shares of MediWound from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Finally, HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of MediWound in a research report on Thursday, May 28th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, MediWound has an average rating of “Hold” and an average target price of $34.00.

MediWound Stock Performance

The stock’s fifty day moving average is $15.44 and its 200 day moving average is $16.82. The stock has a market cap of $190.44 million, a P/E ratio of -6.56 and a beta of 0.14.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.42. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $3.37 million. During the same period in the previous year, the firm posted ($0.07) earnings per share. Equities research analysts predict that MediWound Ltd. will post -2.31 EPS for the current year.

Insider Buying and Selling

In other news, Director David Morton Fox acquired 3,537 shares of the company’s stock in a transaction on Monday, June 1st. The stock was bought at an average cost of $14.11 per share, with a total value of $49,907.07. Following the completion of the purchase, the director directly owned 22,283 shares of the company’s stock, valued at $314,413.13. This represents a 18.87% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 9.20% of the stock is owned by insiders.

Institutional Trading of MediWound

Institutional investors have recently added to or reduced their stakes in the company. Quarry LP bought a new position in shares of MediWound during the fourth quarter valued at approximately $26,000. BNP Paribas Financial Markets boosted its holdings in MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 723 shares during the period. Russell Investments Group Ltd. boosted its holdings in MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 999 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in MediWound in the 4th quarter valued at $109,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.